SE0101675D0 - Novel composition - Google Patents

Novel composition

Info

Publication number
SE0101675D0
SE0101675D0 SE0101675A SE0101675A SE0101675D0 SE 0101675 D0 SE0101675 D0 SE 0101675D0 SE 0101675 A SE0101675 A SE 0101675A SE 0101675 A SE0101675 A SE 0101675A SE 0101675 D0 SE0101675 D0 SE 0101675D0
Authority
SE
Sweden
Prior art keywords
novel composition
methods
pharmaceutical compositions
relates
present
Prior art date
Application number
SE0101675A
Other languages
English (en)
Swedish (sv)
Inventor
Joakim Larsson
Peter Sjoe
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0101675A priority Critical patent/SE0101675D0/xx
Publication of SE0101675D0 publication Critical patent/SE0101675D0/xx
Priority to ARP020101633A priority patent/AR037489A1/es
Priority to KR10-2003-7014579A priority patent/KR20040007547A/ko
Priority to PL02366766A priority patent/PL366766A1/xx
Priority to BR0209431-2A priority patent/BR0209431A/pt
Priority to PCT/SE2002/000875 priority patent/WO2002092571A1/en
Priority to SK13712003A priority patent/SK13712003A3/sk
Priority to CNB02809722XA priority patent/CN1286815C/zh
Priority to CA002446717A priority patent/CA2446717A1/en
Priority to HU0401339A priority patent/HUP0401339A2/hu
Priority to MXPA03010207A priority patent/MXPA03010207A/es
Priority to NZ529302A priority patent/NZ529302A/en
Priority to CZ20033034A priority patent/CZ20033034A3/cs
Priority to IL15851702A priority patent/IL158517A0/xx
Priority to JP2002589457A priority patent/JP2004533452A/ja
Priority to RU2003131679/04A priority patent/RU2281940C2/ru
Priority to EEP200300544A priority patent/EE200300544A/xx
Priority to US10/477,254 priority patent/US7037925B2/en
Priority to EP02733657A priority patent/EP1387830A1/en
Priority to MYPI20021680A priority patent/MY134136A/en
Priority to UA2003109525A priority patent/UA76142C2/uk
Priority to ZA200308350A priority patent/ZA200308350B/en
Priority to IS7016A priority patent/IS7016A/is
Priority to BG108325A priority patent/BG108325A/bg
Priority to NO20034992A priority patent/NO20034992D0/no
Priority to US11/368,914 priority patent/US20060173034A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SE0101675A 2001-05-11 2001-05-11 Novel composition SE0101675D0 (sv)

Priority Applications (26)

Application Number Priority Date Filing Date Title
SE0101675A SE0101675D0 (sv) 2001-05-11 2001-05-11 Novel composition
ARP020101633A AR037489A1 (es) 2001-05-11 2002-05-03 Quinolinas sustituidas y proceso para su preparacion
EP02733657A EP1387830A1 (en) 2001-05-11 2002-05-06 Novel 4-anilinoquinoline-3-carboxamides
CZ20033034A CZ20033034A3 (en) 2001-05-11 2002-05-06 Novel 4-anilinoquinoline-3-carboxamides
IL15851702A IL158517A0 (en) 2001-05-11 2002-05-06 Novel 4-anilinoquinoline-3-carboxamides
BR0209431-2A BR0209431A (pt) 2001-05-11 2002-05-06 Novos compostos de 4-anilinoquinolino-3-carboxamidas
PCT/SE2002/000875 WO2002092571A1 (en) 2001-05-11 2002-05-06 Novel 4-anilinoquinoline-3-carboxamides
SK13712003A SK13712003A3 (en) 2001-05-11 2002-05-06 Novel 4-anilinoquinoline-3-carboxamides
CNB02809722XA CN1286815C (zh) 2001-05-11 2002-05-06 4－苯胺基喹啉－3－甲酰胺类化合物
CA002446717A CA2446717A1 (en) 2001-05-11 2002-05-06 Novel 4-anilinoquinoline-3-carboxamides
HU0401339A HUP0401339A2 (hu) 2001-05-11 2002-05-06 Új 4-anilino-3-kinolinkarboxamidok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
MXPA03010207A MXPA03010207A (es) 2001-05-11 2002-05-06 Nuevas 4-anilinoquinolin-3-carboxamidas.
NZ529302A NZ529302A (en) 2001-05-11 2002-05-06 Novel 4-anilinoquinoline-3-carboxamides
KR10-2003-7014579A KR20040007547A (ko) 2001-05-11 2002-05-06 신규한 4-아닐리노퀴놀린-3-카르복스아미드
PL02366766A PL366766A1 (en) 2001-05-11 2002-05-06 Novel 4-anilinoquinoline-3-carboxamides
JP2002589457A JP2004533452A (ja) 2001-05-11 2002-05-06 新規４−アニリノキノリン−３−カルボキサミド
RU2003131679/04A RU2281940C2 (ru) 2001-05-11 2002-05-06 Ароматические производные 6,7-дизамещенных 3-хинолинкарбоксамидов, способ их получения (варианты), фармацевтическая композиция на их основе и их применение для изготовления лекарства
EEP200300544A EE200300544A (et) 2001-05-11 2002-05-06 4-anilinokinoliin-3-karboksamiidid, nende kasutamine ning valmistamine
US10/477,254 US7037925B2 (en) 2001-05-11 2002-05-06 4-anilinoquinoline-3-carboxamides
MYPI20021680A MY134136A (en) 2001-05-11 2002-05-09 Novel compounds comprising jak3 kinase inhibitors
UA2003109525A UA76142C2 (en) 2001-05-11 2002-06-05 4-anilinoquinoline-3-carboxamides and pharmaceutically acceptable salts thereof and pharmaceutical composition containing them
ZA200308350A ZA200308350B (en) 2001-05-11 2003-10-27 Novel 4-anilinoquinoline-3-carboxamides.
IS7016A IS7016A (is) 2001-05-11 2003-11-05 Ný 4-anilínókínólín-3-karboxamíð
BG108325A BG108325A (bg) 2001-05-11 2003-11-07 Нови 4-анилинохинолин-3-карбоксамиди
NO20034992A NO20034992D0 (no) 2001-05-11 2003-11-10 Nye 4-aninlinokinolin-3-karboksamider
US11/368,914 US20060173034A1 (en) 2001-05-11 2006-03-06 Novel 4-anilinoquinoline-3-carboxamides

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0101675A SE0101675D0 (sv) 2001-05-11 2001-05-11 Novel composition

Publications (1)

Publication Number Publication Date
SE0101675D0 true SE0101675D0 (sv) 2001-05-11

Family

ID=20284085

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0101675A SE0101675D0 (sv) 2001-05-11 2001-05-11 Novel composition

Country Status (25)

Country Link
US (2) US7037925B2 (cs)
EP (1) EP1387830A1 (cs)
JP (1) JP2004533452A (cs)
KR (1) KR20040007547A (cs)
CN (1) CN1286815C (cs)
AR (1) AR037489A1 (cs)
BG (1) BG108325A (cs)
BR (1) BR0209431A (cs)
CA (1) CA2446717A1 (cs)
CZ (1) CZ20033034A3 (cs)
EE (1) EE200300544A (cs)
HU (1) HUP0401339A2 (cs)
IL (1) IL158517A0 (cs)
IS (1) IS7016A (cs)
MX (1) MXPA03010207A (cs)
MY (1) MY134136A (cs)
NO (1) NO20034992D0 (cs)
NZ (1) NZ529302A (cs)
PL (1) PL366766A1 (cs)
RU (1) RU2281940C2 (cs)
SE (1) SE0101675D0 (cs)
SK (1) SK13712003A3 (cs)
UA (1) UA76142C2 (cs)
WO (1) WO2002092571A1 (cs)
ZA (1) ZA200308350B (cs)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576074B2 (en) 2002-07-15 2009-08-18 Rice Kenneth D Receptor-type kinase modulators and methods of use
SE0301373D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
WO2005009971A1 (ja) * 2003-07-24 2005-02-03 Astellas Pharma Inc. キノロン誘導体又はその塩
EP2210607B1 (en) 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
GB0322722D0 (en) * 2003-09-27 2003-10-29 Glaxo Group Ltd Compounds
JP2007518823A (ja) * 2004-01-23 2007-07-12 アムゲン インコーポレイテッド キノリン、キナゾリン、ピリジン、及びピリミジン化合物と炎症、血管新生、及び癌に対する治療におけるそれら化合物の用途
SE0400284D0 (sv) * 2004-02-10 2004-02-10 Astrazeneca Ab Novel compounds
AU2005237254B2 (en) * 2004-05-03 2010-02-04 Novartis Ag Combinations comprising a S1P receptor agonist and a JAK3 kinase inhibitor
BRPI0516093A (pt) 2004-10-12 2008-08-19 Astrazeneca Ab derivado de quinazolina, processo para a preparação do mesmo, composição farmacêutica, uso de um derivado de quinazolina, e, método para tratamento de distúrbios proliferativos celulares em um animal de sanque quente
MX2007004465A (es) * 2004-10-19 2007-05-07 Hoffmann La Roche Derivados de quinolina.
JP2009513615A (ja) 2005-10-28 2009-04-02 アストラゼネカ アクチボラグ 癌の治療においてチロシンキナーゼ阻害剤として使用するための４−（３−アミノピラゾール）ピリミジン誘導体
WO2007099323A2 (en) * 2006-03-02 2007-09-07 Astrazeneca Ab Quinoline derivatives
UY30183A1 (es) * 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
CA2645376C (en) 2006-03-13 2017-06-20 Activx Biosciences, Inc. Aminoquinolones as gsk-3 inhibitors
KR20080112380A (ko) * 2006-04-14 2008-12-24 아스트라제네카 아베 Ｃｓｆ－１ｒ 키나제 억제제로서의 4-아닐리노퀴놀린-3-카르복스아미드
WO2007139496A1 (en) * 2006-05-30 2007-12-06 Clanotech Ab Quinoline derivatives acting as tyrosine kinase inhibitors
TW200829555A (en) * 2006-11-10 2008-07-16 Astrazeneca Ab Chemical compounds
CL2008000191A1 (es) * 2007-01-25 2008-08-22 Astrazeneca Ab Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer.
CN102351880B (zh) * 2007-09-11 2014-11-12 杏林制药株式会社 作为gsk-3 抑制剂的氰基氨基喹诺酮和四唑并氨基喹诺酮
US8476261B2 (en) 2007-09-12 2013-07-02 Kyorin Pharmaceutical Co., Ltd. Spirocyclic aminoquinolones as GSK-3 inhibitors
US8063058B2 (en) 2008-04-16 2011-11-22 Portola Pharmaceuticals, Inc. Inhibitors of syk and JAK protein kinases
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
JP2011520804A (ja) * 2008-05-07 2011-07-21 アストラゼネカ アクチボラグ 化合物
EP2361902A4 (en) * 2008-11-21 2012-04-25 Astellas Pharma Inc 4,6-DIAMINONICOTINSÄUREAMIDVERBINDUNG
NZ779754A (en) 2009-01-16 2023-04-28 Exelixis Inc Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl] oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
MX2011009414A (es) 2009-03-11 2011-10-19 Kyorin Seiyaku Kk 7-cicloalquiloaminoquinolonas como inhibidores de gsk-3.
US8367689B2 (en) 2009-05-06 2013-02-05 Portola Pharmaceuticals, Inc. Inhibitors of JAK
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
CA2806332C (en) 2010-07-30 2017-11-14 Oncotherapy Science, Inc. Quinoline derivatives and melk inhibitors containing the same
UY33549A (es) * 2010-08-10 2012-01-31 Glaxo Group Ltd Quinolil aminas como agentes inhibidores de las quinasas
EP2975027A1 (en) 2010-11-01 2016-01-20 Portola Pharmaceuticals, Inc. Nicotinamides as jak kinase modulators
US9604963B2 (en) 2011-03-04 2017-03-28 Glaxosmithkline Intellectual Property Development Limited Amino-quinolines as kinase inhibitors
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
MX363551B (es) 2011-11-23 2019-03-27 Portola Pharmaceuticals Inc Star Compuestos derivados de pirazina como inhibidores de cinasa.
AR092529A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
TW201425307A (zh) 2012-09-13 2014-07-01 Glaxosmithkline Llc 作為激酶抑制劑之胺基－喹啉類
EP2956138B1 (en) 2013-02-15 2022-06-22 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
MX368903B (es) 2013-02-20 2019-10-21 Kala Pharmaceuticals Inc Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
CA2902132C (en) 2013-02-21 2020-09-22 Glaxosmithkline Intellectual Property Development Limited Quinazolines as kinase inhibitors
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9458169B2 (en) 2013-11-01 2016-10-04 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2016125187A1 (en) * 2015-02-03 2016-08-11 Council Of Scientific & Industrial Research Novel quinoline derivatives and preparation thereof
AU2017324713B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10336767B2 (en) 2016-09-08 2019-07-02 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509423A4 (en) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
CN109496212B (zh) * 2016-10-18 2020-08-14 北京康辰药业股份有限公司 一种喹啉基取代的羧酸化合物或其药学上可接受的盐、其药物组合物及应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3037925A (en) * 1958-04-09 1962-06-05 Smith Corp A O Cathodically protected structure and method of making same
UA73073C2 (uk) * 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
KR20010089171A (ko) * 1998-08-21 2001-09-29 추후제출 퀴나졸린 유도체

Also Published As

Publication number Publication date
IS7016A (is) 2003-11-05
AR037489A1 (es) 2004-11-17
WO2002092571A1 (en) 2002-11-21
US20060173034A1 (en) 2006-08-03
BR0209431A (pt) 2004-08-03
JP2004533452A (ja) 2004-11-04
CN1507434A (zh) 2004-06-23
CZ20033034A3 (en) 2004-06-16
NZ529302A (en) 2004-08-27
NO20034992D0 (no) 2003-11-10
EP1387830A1 (en) 2004-02-11
PL366766A1 (en) 2005-02-07
RU2281940C2 (ru) 2006-08-20
HUP0401339A2 (hu) 2004-12-28
UA76142C2 (en) 2006-07-17
MXPA03010207A (es) 2004-03-10
IL158517A0 (en) 2004-05-12
SK13712003A3 (en) 2004-10-05
KR20040007547A (ko) 2004-01-24
US7037925B2 (en) 2006-05-02
RU2003131679A (ru) 2005-05-10
MY134136A (en) 2007-11-30
BG108325A (bg) 2004-11-30
US20040248923A1 (en) 2004-12-09
CN1286815C (zh) 2006-11-29
HU0401339D0 (en) 2004-08-30
ZA200308350B (en) 2005-01-27
EE200300544A (et) 2004-02-16
CA2446717A1 (en) 2002-11-21

Similar Documents

Publication Publication Date Title
SE0101675D0 (sv) Novel composition
SE0301372D0 (sv) Novel compounds
MXPA05012025A (es) Imidazo y tiazolopiridinas como inhibidores de cinasa jak3.
ATE430747T1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
UA86591C2 (ru) Пирролодигидроизохинолины как ингибиторы pde10, фармацевтическая композиция на их основе
ATE433447T1 (de) Pyrimiidinverbindungen
IL160915A0 (en) Indolizines inhibiting kinase proteins
AU3652102A (en) Compounds and their uses
UA91002C2 (ru) 7-фенилалкилзамещенные 2-хинолиноны и 2-хиноксалиноны как ингибиторы поле(адф-рибоза)полимеразы
MXPA03001982A (es) Amino-aza-cicloalcanos sustituidos utiles contra la malaria.
CY1109006T1 (el) Παραγωγα πουρινης ως αναστολεις κινασης
SE0400284D0 (sv) Novel compounds
AU2003228770A8 (en) Substituted pyrazolopyrimidines
ATE413388T1 (de) Muskarin antagonisten
SE0302139D0 (sv) Novel compounds
DK1456212T3 (da) 6-aminomorphinanderivater, fremgangsmåder til fremstilling heraf og disses anvendelse
IL160171A0 (en) Depsipeptide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
BR0318521A (pt) arilindenopiridinas e arilindenopirimidinas e métodos terapêuticos e profiláticos relacionados
DE60201074D1 (en) Pyrazolopyridinderivate
NO20063293L (no) Farmasoytiske forbindelser
MXPA03010259A (es) Nuevos derivados de 5-tio-ss-d-xilopiranosida, procedimiento de preparacion, composiciones farmaceuticas que los contienen y el uso terapeutico de los mismos.
UY27311A1 (es) Agentes antibacterianos
MXPA05011430A (es) Compuestos lineares basicos antagonistas de nk-2 y formulaciones que los contienen.
WO2005019224A3 (en) Novel antiinfective compounds